Latest news, Wikipedia summary, and trend analysis.
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
4-Allyl-6-oxa-noribogainalog entered the ranking for the first time today at position #. This is its highest position ever recorded.
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-04-14 and was most recently seen on 2026-04-14.
4-Allyl-6-oxa-noribogainalog is a κ-opioid receptor (KOR) agonist of the oxa-ibogalog family related to oxa-noribogaine. It is a highly potent full agonist of the KOR, with an EC50Tooltip half-maximal effective concentration of 1 nM and an EmaxTooltip maximal efficacy of 103% in a G protein BRET assay. This is dramatically more potent at the KOR than oxa-noribogaine or noribogaine in the same assay per another study by the same group (EC50 (Emax) = 43 nM (82%) and 6,100 nM (52%), respectively). The drug shows considerable selectivity for activation of the KOR over activation of the μ- and δ-opioid receptors. 4-Allyl-6-oxa-noribogainalog was the most potent KOR agonist in a series of oxa-ibogalog compounds. It was patented by Dalibor Sames and colleagues in 2025, with Sames being the founder of Gilgamesh Pharmaceuticals.
Read more on Wikipedia →No recent news articles found.
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.